Safety and Efficacy of Exendin 9-39 in Patients With Postbariatric Hypoglycemia
Trial ID or NCT#
This clinical study will evaluate whether taking an investigational drug called exendin 9-39 is safe, well-tolerated, and helps to prevent low blood sugar in people who have had bariatric surgery and later develop a rare condition called postbariatric hypoglycemia (PBH).
A Phase 2, Multicenter, Randomized, Single-Blind, Placebo-Controlled Cross-over Study to Assess the Efficacy and Safety of Exendin 9-39 in Patients With Postbariatric Hypoglycemia
- - Body mass index (BMI) of up to 40 kg/m2 - Roux-en-Y gastric bypass (RYGB) surgery performed ≥12 months prior - Diagnosis of PBH - At least 2 episodes during screening 2-week run-in phase of severe hypoglycemia
- - Other cause of endogenous hyperinsulinism other than PBH - Metabolic or bariatric surgical procedure other than RYGB - History of non-RYGB upper GI surgery - Use of agents that may interfere with glucose metabolism
Contact us to find out if this trial is right for you.